Fresnillo H1 2023 Results: What to Expect

1 Mins read

Revenue Forecast

According to a consensus compiled by Visible Alpha and based on estimates from nine analysts, Mexican precious-metals miner Fresnillo is expected to report total revenue of $1.35 billion for the six months ended June 30. This is an increase from the $1.26 billion reported for the same period last year.

Earnings Forecast

The Visible Alpha consensus predicts that Fresnillo will report earnings before interest, taxes, depreciation, and amortization (EBITDA) of $403.0 million for the first half of 2023. This is slightly lower than the $459.1 million EBITDA reported for the same period last year.

Pre-tax Profit Forecast

Fresnillo is expected to announce a first-half pre-tax profit of $122.8 million, which is down from last year’s figure of $155.2 million.

Key Watch Factors

  1. Costs: Market attention will be focused on the impact of cost headwinds, including inflation and the strengthening of the Mexican peso against the U.S. dollar. Additionally, investors will be interested in any inventory charges or front-loading of exploration costs. Last week, Fresnillo provided commentary on costs in its production update. Consensus estimates suggest that total costs and expenses for the half year will amount to $1.20 billion, compared to $1.04 billion last year.

  2. Production: Investors will be eager for an updated volume guidance for 2024. Analysts from Citi highlight that market interest will be on management confidence regarding the silver production recovery at existing mines and the cost dynamics at the Juanicipio mine. The solid ramp-up delivered by the mine in Q2 2023 makes these areas particularly intriguing.

Stay tuned for Fresnillo’s first-half results on Tuesday.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *